Pharmacokinetics, Safety, and Bioequivalence of Two Empagliflozin Formulations after Single Oral Administration under Fasting and Fed Conditions in Healthy Chinese Subjects: An Open‐label Randomized Single‐dose Two‐sequence, Two‐treatment, Two‐period Crossover Study
Authors:
- 4 June 2020
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 40 (7) , 623-631
Abstract
Objectives: To evaluate the pharmacokinetic properties and safety of empagliflozin, and the bioequivalence of test formulation empagliflozin tablet compared with the brand‐name drug Jardiance (reference formulation) after single oral administration under fasting and fed conditions in healthy Chinese subjects.Methods: An open‐label randomized single‐dose two‐sequence, two‐treatment, two‐period crossover study was conducted in healthy Chinese subjects, with 30 subjects under fasting condition and another 30 subjects under fed condition. Under each condition, subjects received a single oral administration of either the test or reference empagliflozin formulation, and then they received a single oral dose of the other formulation after a 7‐day washout period.Results: A total of 29 subjects under each condition completed the study. The maximum plasma drug concentration, the area under the plasma concentration‐time curve (AUC) from 0 to t (AUC0–t), and the AUC from 0 to infinity (AUC0–∞) of test formulation and reference formulation was 186.90 ± 47.21 and 190.60 ± 40.94 ng/ml, 1303.04 ± 234.28 and 1267.78 ± 217.07 ng·hour/ml, and 1328.08 ± 243.84 and 1293.22 ± 224.82 ng·hour/ml under fasting condition, and 151.55 ± 23.86 and 154.08 ± 30.40 ng/ml, 1215.65 ± 197.62 and 1199.26 ± 186.23 ng·hour/ml, and 1241.76 ± 202.47 and 1225.54 ± 192.10 ng·hour/ml under fed condition, respectively.Conclusions: The two formulations of empagliflozin were bioequivalent, and both were generally well tolerated under fasting and fed conditions.Keywords
This publication has 15 references indexed in Scilit:
- Safety and Tolerability of Empagliflozin in Patients with Type 2 DiabetesClinical Therapeutics, 2016
- Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trialsExpert Opinion on Pharmacotherapy, 2015
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled TrialDiabetes Care, 2014
- Effect of Gemfibrozil, Rifampicin, or Probenecid on the Pharmacokinetics of the SGLT2 Inhibitor Empagliflozin in Healthy VolunteersClinical Therapeutics, 2014
- Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteersInt. Journal of Clinical Pharmacology and Therapeutics, 2013
- Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2013
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese SubjectsDrug Metabolism and Pharmacokinetics, 2013
- The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemiaDiabetes, Obesity and Metabolism, 2011
- Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitorsDiabetes, Obesity and Metabolism, 2011